The risks and the benefits of mesalazine as a treatment for ulcerative colitis

Expert Opinion on Drug Safety

Volumn 6, Issue 2, 2007, Pages 99-107

  Moss, Alan C ^a   Peppercorn, Mark A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Colitis; Efficacy; Mesalazine; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; BALSALAZIDE; ENEMA; ETHYL CELLULOSE; EUDRAGIT; MESALAZINE; MESAVANCE; MICROSPHERE; OLSALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; STEROID; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ALLERGIC REACTION; ALOPECIA; ANTIINFLAMMATORY ACTIVITY; APLASTIC ANEMIA; ARTHRALGIA; BLOOD DYSCRASIA; BRAIN PSEUDOTUMOR; CANCER INHIBITION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENTERITIS; ESOPHAGITIS; FATIGUE; FOLLICULITIS; HEART DISEASE; HEPATITIS; HUMAN; HYPERSENSITIVITY REACTION; INCIDENCE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER DISEASE; LOW DRUG DOSE; LUNG ALVEOLITIS; LUPUS LIKE SYNDROME; MAINTENANCE THERAPY; META ANALYSIS; MONOTHERAPY; MYALGIA; MYOCARDITIS; NAUSEA AND VOMITING; NEPHRITIS; OLIGOSPERMIA; OTALGIA; PANCREATITIS; PATIENT COMPLIANCE; PERICARDIAL EFFUSION; PERICARDITIS; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PNEUMONIA; PREMATURE LABOR; PREVALENCE; PRURITUS; RECURRENT DISEASE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SKIN MANIFESTATION; STILLBIRTH; SYSTEMATIC REVIEW; TABLET; TUBULAR DYSFUNCTION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION; WEAKNESS;

ANIMALS; COLITIS, ULCERATIVE; HUMANS; MESALAMINE; RISK FACTORS;

EID: 33847723392     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.6.2.99     Document Type: Review

References (89)

1. SVARTZ N: Treatment of rheumatoid arthritis with salicylazosulfapyridine. Acta Med. Scand. Suppl. (1958) 341:247-254.
2. SVARTZ N: Salazopyrin, a new Sulfanilamide preparation. Acta. Med. Scand. (1942) 110:577-598.
3. BARON JH, CONNELL AM, LENNARD-JONES JE, JONES FA: Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet (1962) 1:1094-1096.
4. AZAD KHAN AK, PIRIS J, TRUELOVE SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet (1977) 2:892-895.
5. PEPPERCORN MA, GOLDMAN P: The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J. Pharmacol. Exp. Ther. (1972) 181:555-562.
6. PEPPERCORN MA, GOLDMAN P: Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology (1973) 64:240-245.
7. MYERS B, EVANS DN, RHODES J et al.: Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut (1987) 28:196-200.
8. CAMPIERI M, LANFRANCHI GA, BAZZOCCHI G et al.: Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet (1981) 2:270-271.
9. JEWELL DP, TRUELOVE SC: Disodium azodisalicylate in ulcerative colitis. Lancet (1981) 2:1168-1169.
10. DEW MJ, HUGHES PJ, LEE MG, EVANS BK, RHODES J: An oral preparation to release drugs in the human colon. Br. J. Clin. Pharmacol. (1982) 14:405-408.
11. VON MUHLENDAHL KE: [Nephritis from 5-aminosalicylic acid]. Dtsch. Med. Wochenschr. (1989) 114:236.
12. FARRELL RJ, PEPPERCORN MA, FINE SN, MICHETTI P: Mesalamine-associated thrombocytopenia. Am. J. Gastroenterol. (1999) 94:2304-2306.
13. GRIMES DA, SCHULZ KF: Descriptive studies: what they can and cannot do. Lancet (2002) 359:145-149.
14. MOORE N, HALL G, STURKENBOOM M, MANN R, LAGNAOUI R, BEGAUD B: Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol. Drug Saf. (2003) 12:271-281.
15. LAGIER G, VINCENS M, CASTOT A: [Imputability in drug monitoring. Principles of the balanced drug reaction assessment method and principal errors to avoid]. Therapie (1983) 38:303-318.
16. MCCARTAN BE, MCCREARY CE, HEALY CM: Studies of drug-induced lichenoid reactions: criteria for case selection. Oral Dis. (2003) 9:163-164.
17. MEYBOOM RH, HEKSTER YA, EGBERTS AC, GRIBNAU FW, EDWARDS IR: Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf. (1997) 17:374-389.
18. MARTEAU P, NELET F, LE LU M, DEVAUX C: Adverse events in patients treated with 5-aminosalicyclic acid: 1993 - 1994 pharmacovigilance report for Pentasa in France. Aliment. Pharmacol. Ther. (1996) 10:949-956.
19. RANSFORD RA, LANGMAN MJ: Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut (2002) 51:536-539.
20. HEELEY E, RILEY J, LAYTON D, WILTON LV, SHAKIR SA: Prescription-event monitoring and reporting of adverse drug reactions. Lancet (2001) 358:1872-1873.
21. GREEN JR, LOBO AJ, HOLDSWORTH CD et al.: Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology (1998) 114:15-22.
22. HANAUER S, SCHWARTZ J, ROBINSON M et al.: Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am. J. Gastroenterol. (1993) 88:1188-1197.
23. KRUIS W, BRANDES JW, SCHREIBER S et al.: Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment. Pharmacol. Ther. (1998) 12:707-715.
24. LEVINE DS, RIFF, DS PRUITT R et al.: A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am. J. Gastroenterol. (2002) 97:1398-1407.
25. MUNAKATA A, YOSHIDA Y, MUTO T et al.: Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. J. Gastroenterol. (1995) 30(Suppl. 8):108-111.
26. PRUITT R, HANSON J, SAFDI M et al.: Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am. J. Gastroenterol. (2002) 97:3078-3086.
27. RACHMILEWITZ D: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br. Med. J. (1989) 298:82-86.
28. RILEY SA, MANI V, GOODMAN MJ, HERD ME, DUTT S, TURNBERG LA: Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut (1988) 29:669-674.
29. SAFDI M, DEMICCO M, SNINSKY C et al.: A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am. J. Gastroenterol. (1997) 92:1867-1871.
30. SCHROEDER KW, TREMAINE WJ, ILSTRUP DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. (1987) 317:1625-1629.
31. SNINSKY CA, CORT DH, SHANAHAN F et al.: Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann. Intern. Med. (1991) 115:350-355.
32. VECCHI M, MEUCCI G, GIONCHETTI P et al.: Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment. Pharmacol. Ther. (2001) 15:251-256.
33. SUTHERLAND L, MACDONALD JK: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. (2006) 2:CD000543.
34. LOFTUS EV Jr, KANE SV, BJORKMAN D: Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment. Pharmacol. Ther. (2004) 19:179-189.
35. THE MESALAMINE STUDY GROUP: An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. Ann. Intern. Med. (1996) 124:204-211.
36. SUTHERLAND L, MACDONALD JK: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. (2006) 2:CD000544.
37. MANENTI L, DE ROSA A, BUZIO C: Mesalazine-associated interstitial nephritis: twice in the same patient. Nephrol. Dial. Transplant. (1997) 12:2031.
38. AREND LJ, SPRINGATE JE: Interstitial nephritis from mesalazine: case report and literature review. Pediatr. Nephrol. (2004) 19:550-553.
39. WORLD MJ, STEVENS PE, ASHTON MA, RAINFORD DJ: Mesalazine-associated interstitial nephritis. Nephrol. Dial. Transplant. (1996) 11:614-621.
40. CALVINO J, ROMERO R, PINTOS E et al.: Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease. Clin. Nephrol. (1998) 49:265-267.
41. VAN STAA TP, TRAVIS S, LEUFKENS HG, LOGAN RF: 5-Aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology (2004) 126:1733-1739.
42. CORRIGAN G, STEVENS PE: Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment. Pharmacol. Ther. (2000) 14:1-6.
43. IZZEDINE H, SIMON J, PIETTE AM et al.: Primary chronic interstitial nephritis in Crohn's disease. Gastroenterology (2002) 123:1436-1440.
44. ELSEVIERS MM, D'HAENS G, LEREBOURS E et al.: Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy? Clin. Nephrol. (2004) 61:83-89.
45. CALDER IC, FUNDER CC, GREEN CR, HAM KN, TANGE JD: Comparative nephrotoxicity of aspirin and phenacetin derivatives. Br. Med. J. (1971) 4:518-521.
46. DIENER U, TUCZEK HV, FISCHER C, MAIER K, KLOTZ U: Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Naunyn Schmiedebergs Arch. Pharmacol. (1984) 326:278-282.
47. MAHMUD N, O'TOOLE D, O'HARE N, FREYNE PJ, WEIR DG, KELLEHER D: Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. Aliment. Pharmacol. Ther. (2002) 16:207-215.
48. DE JONG DJ, TIELEN J, HABRAKEN CM, WETZELS JF, NABER AH: 5-Aminosalicylates and effects on renal function in patients with Crohn's disease. Inflamm. Bowel Dis. (2005) 11:972-976.
49. SCHWORER H, RAMADORI G: [Acute pancreatitis-adverse effect of 5-aminosalicylic acid (mesalazine) in various galenic dosage forms]. Dtsch. Med. Wochenschr. (2000) 125:1328-1330.
50. FERNANDEZ J, SALA M, PANES J, FEU F, NAVARRO S, TERES J: Acute pancreatitis after long-term 5-aminosalicylic acid therapy. Am. J. Gastroenterol. (1997) 92:2302-2303.
51. GRISHAM MB, WARE K, MARSHALL S, YAMADA T, SANDHU IS: Prooxidant properties of 5-aminosalicylic acid. Possible mechanism for its adverse side effects. Dig. Dis. Sci. (1992) 37:1383-1389.
52. SAEZ J, MARTINEZ J, GARCIA C, GRINO P, PEREZ-MATEO M: Idiopathic pancreatitis associated with ulcerative colitis. Am. J. Gastroenterol. (2000) 95:3004-3005.
53. LANCASHIRE RJ, CHENG K, LANGMAN MJ: Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis. Aliment. Pharmacol. Ther. (2003) 17:887-893.
54. ELAND IA, VAN PUIJENBROEK EP, STURKENBOOM MJ, WILSON JH, STRICKER BH: Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands. Am. J. Gastroenterol. (1999) 94:2417-2422.
55. MAHADEVAN U, KANE S: American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology (2006) 131:283-311.
56. DIAV-CITRIN O, PARK YH, VEERASUNTHARAM G et al.: The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology (1998) 114:23-28.
57. NORGARD B, FONAGER K, PEDERSEN L, JACOBSEN BA, SORENSEN HT: Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut (2003) 52:243-247.
58. KOLASSA N, BECKER R, WIENER H: Influence of sulfasalazine, 5-aminosalicylic acid and sulfapyridine on prostanoid synthesis and metabolism in rabbit colonic mucosa. Prostaglandins (1985) 29:133-142.
59. MOMMA K, HAGIWARA H, KONISHI T: Constriction of fetal ductus arteriosus by non-steroidal anti-inflammatory drugs: study of additional 34 drugs. Prostaglandins (1984) 28:527-536.
60. BANTEL H, BERG C, VIETH M, STOLTE M, KRUIS W, SCHULZE-OSTHOFF K: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am. J. Gastroenterol. (2000) 95:3452-3457.
61. NIKOLAUS S, FOLSCN U, SCHREIBER S: Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology (2000) 47:71-82.
62. STEVENS C, LIPMAN M, FABRY S et al.: 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J. Pharmacol. Exp. Ther. (1995) 272:399-406.
63. ODZE R, ANTONIOLI D, PEPPERCORN M, GOLDMAN H: Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. Am. J. Surg. Pathol. (1993) 17:869-875.
64. MIGLIOLI M, PORRO GB, BRUNETTI G, STURNIOLO GC; THE ITALIAN IBD GROUP: Oral delayed-release mesalazine in the treatment of mild ulcerative colitis: a dose ranging study. Eur. J. Gastroenterol. Hepatol. (1990) 2:229-234.
65. RILEY SA, MANI V, GOODMAN MJ, HERD ME, DUTT S, TURNBERG LA: Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut (1988) 29:669-674.
66. HANAUER SB, SANDBORN WJ, KORNBLUTH A et al.: Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am. J. Gastroenterol. (2005) 100:2478-2485.
67. SUTHERLAND L, MACDONALD JK: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. (2003) 2:CD000543.
68. RUBIN G, HUNGIN AP, CHINN D, DWARAKANATH AD, GREEN L, BATES J: Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. Aliment. Pharmacol. Ther. (2002) 16:1889-1893.
69. SHALE MJ, RILEY SA: Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. (2003) 18:191-198.
70. KANE SV, COHEN RD, AIKENS JE, HANAUER SB: Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am. J. Gastroenterol. (2001) 96:2929-2933.
71. D'HAENS G, HOMMES D, ENGELS L et al.: Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a Phase II, dose-ranging study. Aliment. Pharmacol. Ther. (2006) 24:1087-1097.
72. MARSHALL JK, IRVINE EJ: Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment. Pharmacol. Ther. (1995) 9:293-300.
73. COHEN RD, WOSETH DM, THISTED RA, HANAUER SB: A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am. J. Gastroenterol. (2000) 95:1263-1276.
74. FRIERI G, PIMPO MT, PALUMBO GC et al.: Rectal and colonic mesalazine concentration in ulcerative colitis: oral versus oral plus topical treatment. Aliment. Pharmacol. Ther. (1999) 13:1413-1417.
75. SAFDI M, DEMICCO M, SNINSKY C et al.: A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am. J. Gastroenterol. (1997) 92:1867-1871.
76. MARTEAU P, PROBERT CS, LINDGREN S et al.: Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut (2005) 54:960-965.
77. FOCKENS P, MULDER CJ, TYTGAT GN et al.: Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur. J. Gastroenterol. Hepatol. (1995) 7:1025-1030.
78. D'ALBASIO G, PACINI F, CAMARRI E et al.: Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am. J. Gastroenterol. (1997) 92:1143-1147.
79. PIODI LP, ULIVIERI FM, CERMESONI L, CESANA BM: Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand. J. Gastroenterol. (2004) 39:154-157.
80. MOODY GA, EADEN JA, HELYES Z, MAYBERRY JF: Oral or rectal administration of drugs in IBD? Aliment. Pharmacol. Ther. (1997) 11:999-1000.
81. EADEN JA, ABRAMS KR, MAYBERRY JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut (2001) 48:526-535.
82. VELAYOS FS, TERDIMAN JP, WALSH JM: Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am. J. Gastroenterol. (2005) 100:1345-1353.
83. EADEN J, ABRAMS K, EKBOM A, JACKSON E, MAYBERRY J: Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment. Pharmacol. Ther. (2000) 14:145-153.
84. ALLGAYER H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment. Pharmacol. Ther. (2003) 18(Suppl. 2):10-14.
85. ODES S, VARDI H, FRIGER M et al.: Cost analysis and cost determinants in a european inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology (2006) 131:719-728.
86. MOSS AC, CHEIFETZ AS, PEPPERCORN MA: Combined oral and topical mesalazine treatment for extensive ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. (2006) 3:290-293.
87. KANE S, HUO D, MAGNANTI K: A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin. Gastroenterol. Hepatol. (2003) 1:170-173.
88. GIONCHETTI P, ARDIZZONE S, BENVENUTI ME et al.: A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial. Aliment. Pharmacol. Ther. (1999) 13:381-388.
89. MALCHOW H, GERTZ B: A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. Aliment. Pharmacol. Ther. (2002) 16:415-423.